Page last updated: 2024-11-02

pentobarbital and Diabetes Mellitus, Type 2

pentobarbital has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, YH1
Kim, YS1
Park, CH1
Chung, IY1
Yoo, JM1
Kim, JG1
Lee, BJ1
Kang, SS1
Cho, GJ1
Choi, WS1

Other Studies

1 other study available for pentobarbital and Diabetes Mellitus, Type 2

ArticleYear
Protein kinase C-delta mediates neuronal apoptosis in the retinas of diabetic rats via the Akt signaling pathway.
    Diabetes, 2008, Volume: 57, Issue:8

    Topics: Acetophenones; Animals; Apoptosis; Benzopyrans; Body Weight; Diabetes Mellitus, Type 2; HSP90 Heat-S

2008